Monteloeder debuts Mindrevive, a botanical ingredient for brain health, at SupplySide West 2024

Image | adobe.stock/natali_mis

In an October 22 news release, Monteloeder S.L., a subsidiary of SuanNutra announced details about Mindrevive, an ingredient designed for improving cognition and short-term memory in adults. The compound is made from a combination of extracts from sage and from Japanese pagoda tree, both nootropic ingredients. As noted in the release, sage is known for its antioxidants and anti-cholinesterase activity, while the antioxidant rutin in Japanese pagoda tree has been shown in studies to protect neurons from damage from free radicals.

Mindrevive made its debut at SupplySide West in Las Vegas, Nevada in October 2024.

In an interview with Nutritional Outlook at SupplySide West, Jonathan Jones, PhD, chief scientific officer of Monteloeder, explained that the company "did a lot of research to identify the synergistic effects between these two compounds and how they can benefit people that are looking for products to help them with their memory, attention, and their executive functions. We just finished the clinical trial on this, and we expect to have it published in next few weeks or month. We have very positive results, and we're excited to be [at SupplySide West] with this ingredient.”

Dr. Jones also explained the process behind the formulation of Mindrevive. “When preparing an ingredient for mental health, there's different pathways you can act upon: neuro protection, stress, growth factor, blood flow,” he stated. “We wanted something to be able to provide consumers the complete package and act on different pathways at the same time. That way you can increase the efficacy of the product while also maintaining a low dosage format. So when we saw is that we were able to combine these two [ingredients], we were able to tick every single one of those boxes, targeting specifically memory.”

According to the press release, Mindrevive can be formulated into any dietary supplement format, and research indicates that the optimal dosage of is 400 mg/day.

According to Future Market Insights, the nootropic market is expected to reach nearly US$4.2 billion by 2033, increasing from $2.2 billion in 2023, and worldwide nootropic supplement sales are expected to expand at 9.0% CAGR. “Consumers are actively seeking ways to improve their mental performance, citing reasons such as work-related stress, increased cognitive demands, and a desire to maintain mental sharpness as they age,” stated Maria Ángeles-Gutiérrez, Marketing Director for Suannutra, in the release. “Consumers want natural alternatives that not only enhance cognitive performance but also support overall mental health. Mindrevive taps into current trends in the nootropic space but also aligns with consumer demands for products that promote holistic well-being.”